Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Monitorování imunity a stažení CNI u nízkorizikových příjemců transplantace ledvin

Monitorování imunity a stažení inhibitoru kalcineurinu (CNI) u nízkorizikových příjemců transplantace ledvin

The study will compare how well transplanted kidneys work and the response of people's immune systems as tacrolimus, a calcineurin inhibitor (CNI), is withdrawn. In addition, this research study will evaluate whether reducing immunosuppression can decrease some of these side effects while still preventing rejection of the kidney.

Přehled studie

Detailní popis

Kidney transplantation is a treatment option for people with kidney disease. However, there is still much to learn about how to best care for the transplanted kidney and keep it functioning for a long time. Transplant recipients take immunosuppression (anti-rejection) drugs to prevent their body from rejecting the new kidney. These drugs are used to prevent the immune system from attacking the transplanted kidney. All anti-rejection medications have unwanted side effects. The purpose of this study is to evaluate the safety of slowly removing tacrolimus, a CNI.

Typ studie

Intervenční

Zápis (Aktuální)

52

Fáze

  • Fáze 2

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

    • Manitoba
      • Winnipeg, Manitoba, Kanada, R3A IR9
        • Health Sciences Centre
    • Ontario
      • Toronto, Ontario, Kanada, M5G 2M1
        • Toronto General Hospital
    • California
      • Los Angeles, California, Spojené státy, 90055
        • University of California Los Angeles
    • Connecticut
      • New Haven, Connecticut, Spojené státy, 06520-8029
        • Yale University School of Medicine
    • Massachusetts
      • Boston, Massachusetts, Spojené státy, 02115
        • Brigham & Women's Hospital
    • Michigan
      • Ann Arbor, Michigan, Spojené státy, 48109
        • University of Michigan Hospital
    • Missouri
      • St Louis, Missouri, Spojené státy, 63110
        • Washington University
    • New York
      • New York, New York, Spojené státy, 10029
        • Mount Sinai School of Medicine
    • Ohio
      • Cleveland, Ohio, Spojené státy, 44195
        • Cleveland Clinic Foundation
      • Cleveland, Ohio, Spojené státy, 44106-5048
        • University Hospitals of Cleveland
    • Texas
      • Houston, Texas, Spojené státy, 77030
        • The Methodist Hospital

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

INCLUSION CRITERIA -

Initial Enrollment/Screening: Patients who meet all of the following criteria are eligible for enrollment as study subjects:

  • Subject must be able to understand and provide written informed consent;
  • Primary living-donor (related or unrelated) kidney transplant recipients;
  • Peak flow-based PRAs for class I and class II <30%(performed by local center);
  • Current (within 8 weeks prior to transplantation) flow-based PRAs for class I and class II <30% (performed by local center);
  • No donor specific antibody by flow solid phase method on the peak PRA serum (if serum available), or on the current PRA serum (within 8 weeks prior to transplantation) performed by central core laboratory. If the sera for the peak PRA is not available, then only the current PRA serum will be tested;
  • Negative T-cell and B-cell crossmatch by flow cytometry (performed by local center);
  • Female subjects of childbearing potential must have a negative pregnancy test (urine or serum) upon study entry;
  • Female and male subjects with reproductive potential must agree to use FDA approved methods of birth control while participating in the study.

Inclusion Criteria for Randomization:

Participants who meet all of the following criteria are eligible for randomization:

  • No history of acute rejection episodes;
  • The pre-randomization protocol biopsy should confirm no rejection, including borderline rejection (based on the central pathology read);
  • No donor specific antibody as detected by flow solid phase method (performed by the central core laboratory).

EXCLUSION CRITERIA -

Initial Enrollment/Screening:

Participants who meet any of these criteria are not eligible for enrollment as study subjects:

  • Recipient of multiple organ transplants;
  • Prior history of organ transplantation;
  • Deceased-donor source;
  • Any condition that would preclude protocol biopsies;
  • HLA identical recipients;
  • Currently breast-feeding or plans to become pregnant during the timeframe of the study follow up period;
  • Any condition that, in the opinion of the investigator, would interfere with the subject's ability to comply with study requirements;
  • Inability or unwillingness to comply with study protocol;
  • Use of investigational drugs within 4 weeks of study entry and for the duration of the study;
  • Recent recipient of any licensed or investigational live attenuated vaccine(s) within two months of prior to study entry.

Exclusion Criteria for Randomization:

Participants who meet any of these criteria are not eligible for randomization:

  • Subjects who receive less than 4.5mg/kg of Rabbit ATG (Thymoglobulin®) induction therapy;
  • Subjects who test positive for BKV by PCR in the blood at 6 months post-transplant;
  • Any condition that would preclude protocol biopsies;
  • Currently breast-feeding or plans to become pregnant during the timeframe of the study follow up period;
  • Any condition that, in the opinion of the investigator, would interfere with the subject's ability to comply with study requirements;
  • Inability or unwillingness of a subject to give written informed consent or comply with study protocol;
  • Use of investigational drugs within 4 weeks of study entry and for the duration of the study;
  • Subjects who receive less than 1500 mg daily of Mycophenolate Mofetil (CellCept®) or equivalent.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Tacrolimus (CNI) Withdrawal

Subjects randomized (2:1) to tacrolimus (CNI) withdrawal.

Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a standard immunosuppressive regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.Subjects without any clinical acute rejection (AR) in the first 6 months, without borderline or acute rejection on the 6 month biopsy, and without donor-specific antibody (DSA) at anytime, including the 6 month test are randomized (2:1) to tacrolimus (CNI) withdrawal.

Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.

Subjects without any clinical acute rejection (AR) in the first 6 months, without borderline or acute rejection on the 6 month biopsy, and without donor-specific antibody (DSA) at anytime, including the 6 month test will be randomized (2:1) to tacrolimus (CNI) withdrawal.

Ostatní jména:
  • Thymoglobulin®
  • mykofenolát mofetil
  • CellCept®
  • Indukce ATG, takrolimus (CNI), MMF a prednison, následuje stažení CNI
  • králičí antithymocytární globulin (RATG)
  • inhibitor kalcineurinu (CNI)

Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.

Ostatní jména:
  • Thymoglobulin®
  • mykofenolát mofetil
  • CellCept®
  • králičí antithymocytární globulin (RATG)
  • inhibitor kalcineurinu (CNI)
  • ATG indukce, takrolimus (CNI), MMF a prednison
Aktivní komparátor: Standard Immunosuppressive Therapy

Subjects randomized to standard immunosuppressive therapy, without subsequent tacrolimus (CNI) withdrawal.

Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a standard immunosuppressive regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus. Tacrolimus (CNI) withdrawal does not occur.

Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.

Ostatní jména:
  • Thymoglobulin®
  • mykofenolát mofetil
  • CellCept®
  • králičí antithymocytární globulin (RATG)
  • inhibitor kalcineurinu (CNI)
  • ATG indukce, takrolimus (CNI), MMF a prednison

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Percentage of Participants With Incremental IF/A Scores >2 at 24 Months Post-Randomization
Časové okno: IF/TA scores on protocol biopsies obtained at 24 months post-randomization will be compared to those obtained at the time of implantation for this measurement.

The investigators were not able to assess this outcome, the effect of the intervention on interstitial fibrosis/tubular atrophy (IF/TA; on a 2-year graft biopsy) due to the study's premature termination by the Data Safety Monitoring Board (DSMB) because of absence of equipoise on the basis of predetermined stopping rules.

IF/TA scores on protocol biopsies obtained at 24 months post-randomization will be compared to those obtained at the time of implantation for this measurement.

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Estimated GFR Using the Chronic Kidney Disease Epidemiology (CKD-EPI) Equation
Časové okno: 6 months post-transplantation, 24 months post-transplantation

Estimated glomerular filtration rate (eGFR) is a test to measure the level of kidney function. In this measure, the effects of tacrolimus withdrawal on long-term kidney function was assessed by comparing absolute 24 month eGFR (18 months post-randomization) and change in eGFR from 6 to 24 months (randomization to 18 months randomization). Lower numbers indicate poorer kidney function

6 months post-transplantation, 24 months post-transplantation
Incidence of Acute Rejection
Časové okno: 6 to 18 months post-randomization

Acute renal allograft rejection is defined as histological reading of borderline or greater determined by the local pathology laboratory. Participants suspected of having a rejection episode on the basis of clinical signs, symptoms, or on the basis of laboratory tests, had a renal ultrasound and underwent a renal transplant biopsy. Any detection of acute cellular rejection or acute humoral rejection resulted in participants in the 'Randomized to Tacrolimus Withdrawal' group to be restarted on tacrolimus and followed per the reduced follow-up schedule of events.

6 to 18 months post-randomization
Allograft Survival Rate
Časové okno: 6 to 18 months post-randomization

Allograft survival is defined as participants who did not need to be re-transplanted or placed on dialysis due to the failure of their allograft transplantation during the course of this study.

6 to 18 months post-randomization
Participant Survival Rate
Časové okno: 6 to 18 months post-transplantation

Number of participants who did not die within the course of this study.

6 to 18 months post-transplantation
Percentage of Participants With New Donor Specific Antibodies (DSAs)
Časové okno: 6 to 18 months post-randomization

Donor specific antibodies are antibodies that are directed against antigens expressed on donor organs. These antibodies can result in an immune attack on the transplanted organ, increasing risk of graft loss and/or rejection.

6 to 18 months post-randomization
Percentage of Participants With Donor-Specific Memory Using Elispot
Časové okno: 6 to 18 months post-randomization

This endpoint was unable to be analyzed because the study was terminated early after stopping rules were met.

6 to 18 months post-randomization
Percentage of Participants in the Experimental Arm Off Tacrolimus
Časové okno: 18 months post-randomization

Participants in the 'Randomized to Tacrolimus Withdrawal' group were considered fully withdrawn once they no longer received any doses of tacrolimus. Participants met this endpoint if they did not resume taking tacrolimus as of 18 months post randomization with stable allograft function and without rejection of donor-specific antibodies.

18 months post-randomization
Incremental Change in IF/TA Scores
Časové okno: 6 to 18 months post-transplant

This endpoint was unable to be analyzed because the study was terminated early after stopping rules were met.

6 to 18 months post-transplant
Measurement of Urinary Parameters Before and After Randomization
Časové okno: 6 months post-transplantation to 18 months post-randomization

This endpoint was unable to be analyzed because the study was terminated early after stopping rules were met.

6 months post-transplantation to 18 months post-randomization

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Vyšetřovatelé

  • Studijní židle: Donald Hricik, MD, University Hospitals Cleveland Medical Center
  • Vrchní vyšetřovatel: Peter S. Heeger, MD, Icahn School of Medicine at Mount Sinai

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia

1. listopadu 2010

Primární dokončení (Aktuální)

1. května 2015

Dokončení studie (Aktuální)

1. května 2015

Termíny zápisu do studia

První předloženo

20. ledna 2012

První předloženo, které splnilo kritéria kontroly kvality

20. ledna 2012

První zveřejněno (Odhadovaný)

25. ledna 2012

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

24. září 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

22. září 2026

Naposledy ověřeno

1. září 2026

Více informací

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit